Healthcare Reform and Comparative Effectiveness


Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at

SKU: 2137. Categories: , .

Product Description

We all know that R&D focus, pharmaceutical promotion, pricing, and reimbursement are all, or will be, critically affected by the biggest U.S. healthcare reform to occur in 40 years. The impact is going to be disruptive, but overall, experts says it will be a positive gain for the pharmaceutical industry. According to several reports published in March 2010, after the bill was passed, the financial impact on pharma will be negative to 2014, then turn positive between 2014 and 2019. Overall, research analysts predict that the net financial impact will be neutral. Processes and strategies, on the other hand, will need to change dramatically to adapt to new terms, and the industry needs to evaluate its responses to the new bill in three time frames: short-term, mid-term, and long-term.
According to Dave Provost, VP, post-approval services, INC Research, CER needs to be considered for its near-term as well as long-term…

Clear Actions for Meeting the Challenges of CER
IMS Provides Answers to Meeting the Challenges of CER

Carolyn Buck Luce. Global Pharmaceutical Leader, Ernst & Young, helps companies across the globe to identify and capitalize on business opportunities. For more information, visit
Thomas Fussaro. Director, Government Relations and Public Policy, Millennium: The Takeda Oncology Company, which is focused exclusively in oncology to improve the treatment of cancer around the world. For more information, visit
Mark Gianforcaro. Chief Marketing Officer, i3, which takes a 360-degree view of healthcare to help its global pharmaceutical, biotechnology, and medical device customers bring safe and effective products to market quickly and help demonstrate their value, leading to increased ROI and better patient care. For more information, visit
Richard Gliklich, M.D. President and CEO, Outcome Sciences Inc., which provides patient registries, technologies for evaluating real-world outcomes, and quality reporting services for healthcare providers. For more information, visit
Melissa Hammond. Managing Director, Snowfish LLC, which integrates clinical, marketing, and quantitative information to answer a client’s specific objective. For more information, visit
Terry Hisey. Vice Chairman, U.S. Life Sciences Leader, Deloitte offers a menu of professional services delivered in an integrated, collaborative approach that cuts across all segments of the health plan, health provider, and life-sciences industries. For more information, visit
David Merkel. Senior VP Business Development, J. Knipper and Company Inc., a provider of ­healthcare marketing solutions in direct marketing, ­sampling, compliance, information technology, and ­sales force productivity. For more information, visit ­
Dave Provost. VP, Post-Approval Services, INC Research is a therapeutically focused global contract research organization with expertise and a reputation for conducting global clinical development programs of the highest integrity. For more information, visit
Jonothan Tierce. General Manager, Health ­Economics & Outcomes Research, IMS Health offers ­market intelligence products and services. For mor ­information, visit
Stephen Webb. President, North America, Registrat MAPI is a CRO dedicated to providing late-phase research to the global biopharma and medical-device industries. For more information, visit
Claudia Wiatr. Senior Principal, Wolters Kluwer inThought brings together the data assets and resources available at Wolters Kluwer Pharma Solutions to provide a portfolio of analytical and forecasting ­products and services to both the financial and pharmaceutical markets. For more information, visit